The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423139 | PMC |
| http://dx.doi.org/10.1097/ICO.0000000000002642 | DOI Listing |
Publication Analysis
Top Keywords
fuchs endothelial
12
endothelial corneal
12
corneal dystrophy
12
clinical efficacy
8
efficacy rho-associated
8
rho-associated protein
8
protein kinase
8
eye drops
8
close clinical
4
kinase inhibitor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!